The Directorate of Revenue Intelligence (DRI) has busted an illicit laboratory manufacturing alprazolam in Delhi's Ghazipur area, seizing 148 kg of alprazolam intermediate and arresting the person operating the facility, according to an agency statement issued through the Press Information Bureau on Wednesday. The premises were reportedly operating under the façade of a computer shop.
According to the DRI, officers searched the premises on 15 and 16 November 2026. The search revealed a fully functional clandestine laboratory equipped with reaction apparatus, a water chiller, a vacuum exhaust machine and other equipment used in the manufacturing process, the agency said. The accused has not been named.
Besides the 148 kg of alprazolam intermediate in solid and liquid form, officers seized approximately 1,046 kg of raw materials and chemicals, along with 188 litres of additional chemicals and liquids used in manufacturing. The equipment and materials were seized under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, under which the case will be tested.
Alprazolam is a benzodiazepine-class psychotropic substance, commonly sold under brand names such as Xanax and Alprax, and is a prescription medicine used mainly for anxiety and panic disorders. It is a notified psychotropic substance under the NDPS Act, and its unauthorised manufacture, possession, sale and distribution attract penal provisions. The DRI said its misuse, dependence potential and diversion into illicit channels pose significant public health concerns.
The operation was intelligence-led, the DRI said. It follows the agency's busting of a clandestine synthetic drug laboratory in Jalaun district of Uttar Pradesh on 29 October 2026, with operational assistance from the Uttar Pradesh Anti-Terrorism Squad. That operation led to the seizure of approximately 1,100 kg of drugs and precursor chemicals, along with manufacturing equipment, and the arrest of two persons. The DRI said the Delhi bust within weeks of the Jalaun operation underscores its intensified focus on identifying and dismantling illicit drug manufacturing facilities.
